Placebo News and Research

RSS

Clinical trial to evaluate antiviral drug for monkeypox begins in the Democratic Republic of the Congo

A clinical trial to evaluate the antiviral drug tecovirimat, also known as TPOXX, in adults and children with monkeypox has begun in the Democratic Republic of the Congo (DRC).

12 Oct 2022

What is the real-world efficacy of oral antivirals against the SARS-CoV-2 Omicron variant?

A new review commented on a previous study regarding the real-world effectiveness of oral antivirals against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant.

12 Oct 2022

Clinical trial to test the safety, efficacy of bacteriophages for treating P. aeruginosa infections in CF patients

Cystic fibrosis (CF) is an inherited disorder that causes severe damage to the lungs and other organs in the body.

11 Oct 2022

Cat allergen immunotherapy works better and more quickly when combined with monoclonal antibody

An experimental approach to enhancing a standard cat allergy treatment made it more effective and faster acting, and the benefits persisted for a year after treatment ended, a study supported by the National Institutes of Health has found.

11 Oct 2022

Clinical trials of novel COVID-19 vaccine developed in Brazil to begin soon

Testing on humans of a novel COVID-19 vaccine developed in Brazil will begin this year. It performed well in animal trials, as reported in an article published in August in Nature Communications.

6 Oct 2022

Novel protein vaccine NVX-CoV2373 triggered functional T cell responses to SARS-CoV-2

Researchers determined the T cell response to the NVX-CoV2373, an adjuvanted recombinant full-length SARS-CoV-2 spike (S) trimer protein vaccine.

5 Oct 2022

Early-stage clinical trial evaluating bacteriophage therapy in adults with cystic fibrosis begins

Enrollment has begun in an early-stage clinical trial evaluating bacteriophage therapy in adults with cystic fibrosis (CF) who carry Pseudomonas aeruginosa (P. aeruginosa) in their lungs.

4 Oct 2022

What are the challenges of COVID-19 vaccination and herd immunity?

A new study reviewed the challenges of coronavirus disease 2019 (COVID-19) vaccination and herd immunity.

4 Oct 2022

Social motivator effectively rescues rehab participation in mice after spinal cord injury

A research finding in mice that the drug gabapentin improved rehab compliance after spinal cord injury led scientists to a related, unexpected discovery: Injured mice that didn't receive gabapentin and declined to exercise by themselves were willing to hop on the treadmill when presented with a group rehab option.

3 Oct 2022

Extended-release nifedipine could help treat women with severe preeclampsia during labor and delivery

Women with severe preeclampsia (severe high blood pressure) during pregnancy may be treated with extended-release nifedipine, a blood pressure-lowering medicine, daily during the labor and delivery process, according to new research published today in Hypertension, an American Heart Association journal.

3 Oct 2022

One-time test predicts which hospitalized COVID-19 patients are likely to worsen, study finds

A one-time test could predict which people hospitalized with COVID-19 are likely to worsen significantly during their stay, even if they were admitted with relatively mild symptoms, according to a study of more than 2,500 people headed by researchers at Stanford Medicine.

27 Sep 2022

Designing a new treatment to treat migraine effectively

In this interview, we speak to Mudra Kapoor, Vice President of Global Medical Affairs for Neuroscience at AbbVie, about atogepant, their new treatment option for migraine.

From AbbVie 26 Sep 2022

Trial tests efficacy and safety of NVX-CoV2373 COVID-19 vaccine among adolescents

In a recent study posted to the medRxiv* preprint server, researchers in the United States described the safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), tested in PREVENT-19 — a phase 3, randomized, placebo-controlled, observer-blinded trial among 12- to 17-year-old adolescents in the United States (U.S).

25 Sep 2022

Blueberries, a tasty intervention against age-related cognitive decline

In a recent study published in the Nutritional Neuroscience journal, researchers assessed the impact of consumption of wild blueberries on the speed of processing in mild cognitive decline.

25 Sep 2022

Anti-fibrotics found to be safe, effective for interstitial lung disease in patients with rheumatoid arthritis

For the first time, researchers have shown that a class of anti-fibrotic drugs slows the progression of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA).

22 Sep 2022

Healthy people with high cholesterol don't stand to benefit from statins, research says

About 40 million adults in the United States regularly take statins to lower their cholesterol levels and reduce their risk of heart disease and stroke, according to American Heart Association data from 2020.

20 Sep 2022

Rheumatoid arthritis drug can reduce the risk of deterioration in myasthenia gravis

Early intervention with rituximab, a drug used in the treatment of rheumatoid arthritis (RA), can reduce the risk of deterioration in myasthenia gravis, an autoimmune disease that causes loss of muscle control.

19 Sep 2022

Daily multivitamin improves cognitive function in seniors

In a recent study published in the journal Alzheimer's & Dementia, researchers in the United States investigated whether daily administration of a cocoa extract (CE, comprising 500 mg flavanols, including 80 mg epicatechins, 50 mg/day theobromine (50 mg/day), and 15mg/day caffeine) and/or an MVM (multivitamin-mineral) for three years protected cognitive functions among older men and women.

18 Sep 2022

UCLA announces participation in a phase 3 trial evaluating tecovirimat for the treatment of monkeypox

The UCLA Clinical AIDS Research and Education (CARE) Center today announced its participation in STOMP (Study of Tecovirimat for Human Monkeypox Virus), or A5418, a phase 3, randomized, placebo-controlled, double-blind trial evaluating the safety and efficacy of tecovirimat for the treatment of human monkeypox.

16 Sep 2022

UW Medicine researchers seek participants for Phase 3 clinical trial of a drug to treat monkeypox

UW Medicine researchers are recruiting participants for a Phase 3 clinical trial of a drug to treat the monkeypox virus.